Instrument Inactif

Communiqués Rubius Therapeutics

Actions

RUBY

US78116T1034

Communiqués

06/04/23	RUBIUS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
03/03/23	RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	AQ
27/02/23	RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
22/02/23	RUBIUS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
06/02/23	RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	AQ
21/12/22	Rubius Therapeutics : Acquisition/Asset Disposal - Form 8-K	PU
21/12/22	RUBIUS THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets (form 8-K)	AQ
14/12/22	Rubius Therapeutics : Termination of Material Agreement - Form 8-K	PU
14/12/22	RUBIUS THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
12/12/22	RUBIUS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
09/11/22	RUBIUS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
02/11/22	RUBIUS THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)	AQ
02/11/22	Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes	GL
17/10/22	RUBIUS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
13/10/22	Rubius Therapeutics : Accelaration/Increase of Financial Obligation - Form 8-K	PU
13/10/22	RUBIUS THERAPEUTICS, INC. : Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement (form 8-K)	AQ
19/09/22	Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference	GL
19/09/22	Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference	AQ
13/09/22	RUBIUS THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/09/22	Rubius Therapeutics Announces Strategic Update	AQ
13/09/22	Rubius Therapeutics Announces Strategic Update	GL
12/09/22	Rubius Therapeutics to Provide Strategic Update	GL
12/09/22	Rubius Therapeutics to Provide Strategic Update	AQ
12/08/22	RUBIUS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	AQ
10/08/22	Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update	AQ